Raxatrigine
 | |
| Clinical data | |
|---|---|
| Routes of administration | Oral |
| ATC code | None |
| Identifiers | |
| |
| CAS Number |
934240-30-9 934240-35-4 (mesylate) |
| PubChem (CID) | 16046068 |
| ChemSpider | 13174481 |
| Chemical and physical data | |
| Formula | C18H19FN2O2 |
| Molar mass | 314.354063 g/mol |
| 3D model (Jmol) | Interactive image |
| |
| |
Raxatrigine (INN, USAN) (formerly CNV1014802, GSK-1014802) is a novel analgesic under development by Convergence Pharmaceuticals for the treatment of lumbosacral radiculopathy (sciatica) and trigeminal neuralgia (TGN).[1][2][3] It acts as a selective, small-molecule, state-dependent Nav1.7 voltage-gated sodium channel blocker.[1][2] In June 2014, Convergence presented positive results for a phase II clinical study of raxatrigine in the treatment of TGN, including findings that the drug had an excellent efficacy and safety profile and was well-tolerated.[4]
See also
References
- 1 2 Convergence Pharmaceuticals. "CNV1014802 - Convergence Pharmaceuticals".
- 1 2 Stephen McMahon; Martin Koltzenburg; Irene Tracey; Dennis C. Turk (1 March 2013). Wall & Melzack's Textbook of Pain: Expert Consult - Online. Elsevier Health Sciences. p. 508. ISBN 0-7020-5374-0.
- ↑ Bagal, Sharan K.; Chapman, Mark L.; Marron, Brian E.; Prime, Rebecca; Ian Storer, R.; Swain, Nigel A. (2014). "Recent progress in sodium channel modulators for pain". Bioorganic & Medicinal Chemistry Letters. 24 (16): 3690–9. doi:10.1016/j.bmcl.2014.06.038. ISSN 0960-894X. PMID 25060923.
- ↑ MarketWatch (2014). "Convergence Pharmaceuticals' Novel Sodium Channel Blocker CNV1014802 Shows Excellent Efficacy and Safety in Ground-breaking Phase II Trigeminal Neuralgia Study".
This article is issued from Wikipedia - version of the 11/3/2016. The text is available under the Creative Commons Attribution/Share Alike but additional terms may apply for the media files.